Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Next Stem Cell President Should be Hands-on, Scientific Administrator; Consumer Advocates Urge

Published: Monday, February 05, 2007
Last Updated: Monday, February 05, 2007
Bookmark and Share
Focusing on big names could result in hiring a figurehead rather than an executive committed to making the stem cell institute work in the public's best interest.

California's stem cell oversight committee should focus on finding a competent, hands-on administrator to replace retiring Dr. Zach Hall as president of the California Institute for Regenerative Medicine (CIRM), said the Foundation for Taxpayer and Consumer Rights (FTCR).

"Members of the search committee should avoid the temptation of seeking a 'big-name' scientist known for his or her discoveries," said John M. Simpson, FTCR Stem Cell Project Director. "The emphasis must be on the individual's skills in scientific management and administration."

Focusing on big names could result in hiring a figurehead rather than an executive committed to making the stem cell institute work in the public's best interest, FTCR said.

The presidential search committee meets at 3 p.m. Wednesday, Jan. 31, in San Francisco. In a letter to Robert Klein committee chairman, Simpson said that Dr. Hall had exemplified the qualities necessary for the position during his two years in the job.

"The next president must be an extremely competent hands-on scientific administrator, who can set up and maintain transparent and accountable management systems," Simpson wrote. "He or she must be able to interact with the public, state officials, legislators and the media in a transparent, honest and accountable fashion."

In the past there have been suggestions that the president of the California Institute for Regenerative Medicine (CIRM) might continue to maintain a research laboratory as part of the president's role. This should not be allowed, FTCR said.

"The presidency of CIRM is more than a full-time job, "said Simpson.”A person trying to manage CIRM's activities and conduct meaningful research simultaneously would do justice to neither activity."

Finally, while there are a number of individuals on the ICOC itself who have performed admirably in their positions as scientific administrators, FTCR said CIRM's interests would be best served if the search does not consider them and looks beyond the oversight committee.

Dr. Hall announced at the stem cell oversight committee's December meeting that he wished to retire within six months.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

California Stem Cell Agency Exaggerated its Role in Funding Key Research
California's stem cell agency overstated and hyped the importance of its funding in enabling clinical trials for a drug to treat a severe blood disorder.
Thursday, April 17, 2008
CIRM to Announce new Faculty Awards to Fund Next Generation of Stem Cell Scientists
CIRM will announce up to $85 million in New Faculty Awards at the December 12 meeting of its governing body, the Independent Citizens Oversight Committee.
Tuesday, December 11, 2007
Stem Cell Research Headed by $45 Million in California
The 29-member Independent Citizens Oversight approves 72 grants to researchers at 20 academic and non-profit research centers throughout the state.
Friday, February 23, 2007
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!